JANX — Janux Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1817713 ·
Last close
$16.30
Market Cap
$996.53M
52W High
$35.34
52W Low
$12.12
ADV30
943,300
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 10,267,000 | — | -31,690,000 | -21,972,000 | 1,007,653,000 | 27,768,000 | 79,669,000 |
| Mar 2026 | 3,733,000 | — | -34,213,000 | -24,361,000 | 1,028,225,000 | 51,828,000 | 86,690,000 |
| Dec 2025 | 0 | — | -42,401,000 | -31,946,000 | 1,001,565,000 | 52,334,000 | 44,743,000 |
| Sep 2025 | 10,000,000 | — | -35,251,000 | -24,313,000 | 1,024,766,000 | 48,389,000 | 48,211,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,251,000
Investing CF
$7,351,000
Financing CF
$9,222,000
CapEx
$-674,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.64
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-397,715,000
Inventory
—
Receivables
$6,325,000
ST Investments
$943,145,000
EBIT TTM
$-143,555,000
Pretax Income TTM
$-102,592,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$24,000,000
EBITDA
$-141,654,000
Free Cash Flow
$-16,392,875
Enterprise Value
$95,515,816
Total Cash
$970,913,024
Total Debt
$20,990,000
Shares Out
61,136,773
Trailing EPS
$-1.64
Book Value
$15.19
ROE
-10.7%
ROA
-8.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,000,000 | -157,667,000 | -113,625,000 | 1,001,565,000 | 44,743,000 | 956,822,000 | -82,235,000 |
| Dec 2024 | 10,588,000 | -98,847,000 | -68,994,000 | 1,061,516,000 | 38,735,000 | 1,022,781,000 | -43,814,000 |
| Dec 2023 | 8,083,000 | -72,979,000 | -58,293,000 | 380,407,000 | 36,058,000 | 344,349,000 | -50,575,000 |
| Dec 2022 | 8,612,000 | -67,091,000 | -63,059,000 | 364,010,000 | 43,270,000 | 320,740,000 | -42,922,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.62
Max Pain — expiry 2028-01-21
max pain strike: $17.50 · spot: $16.67 · call oi: 1,398 · put oi: 1,862
Expected Move to 2028-01-21:
±$10.50
(62.99%) —
implied range
$6.17 –
$27.17
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCRX | Pacira BioSciences, Inc. | $1.00B | $25.12 | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $977.49M | $11.62 | — |
| MLTX | MoonLake Immunotherapeutics | $1.02B | $12.04 | — |
| SVRA | Savara Inc | $1.03B | $5.00 | — |
| ABUS | Arbutus Biopharma Corp | $960.81M | $4.85 | — |
News headlines (Yahoo Finance, 1h cache)
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
2026-09-14 12:00 · Yahoo
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?
2026-06-30 13:06 · Yahoo
Here's Why You Should Add JANX Stock to Your Portfolio Now
2026-05-26 15:28 · Yahoo
Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey
2026-09-27 15:07 · Yahoo
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
2026-09-16 09:47 · Yahoo
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
2026-09-15 14:12 · Yahoo
Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls
2026-08-24 13:54 · Yahoo
Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More
2026-08-24 11:49 · Yahoo
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
2026-08-21 14:52 · Yahoo
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile
2026-08-11 10:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.